Detection of cognitive deficits years prior to clinical diagnosis across neurological conditions
Xin You Tai,Sofia Toniolo,David Llewellyn,Cornelia Van Duijn,Masud Husain,Sanjay G Manohar
DOI: https://doi.org/10.1101/2024.07.10.24310213
2024-07-10
Abstract:Importance: Understanding the cognitive trajectory of a neurological disease can provide important insight on underlying mechanisms and disease progression. Cognitive impairment is now well established as beginning many years before the diagnosis of Alzheimer's disease, but pre-diagnostic profiles are unclear for other neurological conditions that may be associated with cognitive impairment.
Objective: Compare pre-diagnostic and post-diagnostic cognition and global brain volume in ischaemic stroke, focal epilepsy, Parkinson's disease, multiple sclerosis, motor neurone disease (amyotrophic lateral sclerosis) and migraine using time-to-diagnosis and time-from-diagnosis data in relation to time of assessment.
Design: Analysis the prospective UK Biobank cohort with study baseline assessment performed between 2006-2010 and participants followed until 2021.
Setting: Multicenter, population-based study.
Participants: Sample of 497,252 participants, aged between 38 and 72 years, at baseline with an imaging sub-sample of 42,468 participants.
Exposure: Participants with each neurological condition were compared to a healthy control group.
Main outcomes and measures: A continuous measure of executive function and magnetic resonance imaging brain measures of total grey matter and hippocampal volume.
Results: Of the 497,252 participants (226,206 [45.5%] men, mean [SD] age, 57.5[8.1] years), 12,755 had ischaemic stroke, 6,758 had a diagnosis of focal epilepsy, 3,315 had Parkinson's disease, 2,315 had multiple sclerosis, 559 had motor neurone disease and 18,254 had migraine either at study baseline or diagnosed during the follow-up period. Apart from motor neurone disease, all conditions had lower pre-diagnosis executive function compared to controls (assessment performed median 7.4 years before diagnosis). Participants with focal epilepsy and multiple sclerosis showed a gradual worsening in executive function up to 15 years prior to diagnosis, while ischaemic stroke was characterised by a modest decline for a few years followed by a substantial reduction at the time of diagnosis. By contrast, participants with migraine showed improved post-diagnosis cognitive scores. Pre-diagnosis MRI grey matter volume was lower than controls for stroke, Parkinson's disease and multiple sclerosis (scans performed median 1.7 years before diagnosis), while other conditions had lower volumes post-diagnosis.
Conclusion: These cognitive trajectory models reveal disease-specific temporal patterns, including a long cognitive prodrome associated with focal epilepsy and multiple sclerosis. The findings may help to prioritise risk management of individual diseases and inform clinical decision-making.
Neurology